Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.
Lung Cancer, Non-Small Cell
DRUG: Tislelizumab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed Disodium
Pathological complete response (pCR) rate, Up to 3 months following completion of neoadjuvant treatment
Major pathological response (MPR) rate, Up to 3 months following completion of neoadjuvant treatment|Objective Response Rate (ORR), Up to 3 years|Event-free survival (EFS), Up to 3 years|Overall survival (OS), Up to 3 years|Number of participants experiencing treatment-emergent adverse events (TEAEs), Up to 3 years
The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.